fig2

Temozolomide exposure and delivery barriers in glioma: cross-compartment pharmacokinetics and implications for resistance

Figure 2. Proposed research roadmap from an exposure deficit to clinical benefit. Each step links a mechanistic question to a measurable endpoint. MGMT and MMR are considered separately. Progression criteria require prospective definition and validation; this framework does not prescribe patient treatment. This figure was created by the authors using Python/python-pptx and LibreOffice. No AI-based image-generation tools or third-party graphical elements were used. MGMT: O6-Methylguanine-DNA methyltransferase; MMR: mismatch-repair; TMZ: temozolomide.